Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04654260 · ClinicalTrials.gov registry record · NA

Behavior Therapy for Irritability in Autism

A NA study of Autism Spectrum Disorder and Aggression, sponsored by Yale University.

Active
Registry status
NA
Development phase
65
Enrollment target
1
Study location

NCT04654260: Active NA study of Autism Spectrum Disorder and Aggression, sponsored by Yale University.

NCT04654260 is a NA study of Autism Spectrum Disorder and Aggression that is active but no longer recruiting, run by Yale University. The registered enrollment target is 65 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04654260, a NA study of Autism Spectrum Disorder and Aggression, is active but no longer recruiting, sponsored by Yale University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

This is a clinical trial of a novel intervention, Behavioral Therapy for Irritability and Aggression (BTIA), for adolescents on the autism spectrum. The main goals of BTIA are to help adolescents develop emotion regulation skills to handle frustration and to strengthen skills for navigating the challenging and diverse experiences associated with the transition to adulthood. The study will test whether BTIA can be helpful to adolescents on the autism spectrum and to their families.

Primary Outcome

Modified Overt Aggression Scale is a 16-item scale that reflects the frequency and severity of incidents of aggressive behavior. Scores can range from 0 (minimum) to 300 (maximum) with higher scores reflecting worse outcome.

Interventions

  • BEHAVIORAL Behavioral Therapy for Irritability in Autism
  • BEHAVIORAL Psychoeducation and Supportive Therapy (PST)

Study Locations (1)

Connecticut

  • Yale Child Study Center - New Haven

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2020-12-10
Est. Completion 2026-02
Phase NA
Yale University

1,492 total trials

What the registry record for NCT04654260 still lists

NCT04654260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (52% lower).

The record links to 7 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Behavioral Therapy for Irritability in Autism is the first listed.

NCT04654260 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT04654260 about?

NCT04654260 is a clinical study titled "Behavior Therapy for Irritability in Autism". This is a clinical trial of a novel intervention, Behavioral Therapy for Irritability and Aggression (BTIA), for adolescents on the autism spectrum. The main goals of BTIA are to help adolescents develop emotion regulation skills to handle frustration and to strengthen skills for navigating the chal...

What is the current status of trial NCT04654260?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2020-12-10. Estimated completion is 2026-02.

What conditions does trial NCT04654260 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, Aggression, Anger, Asperger Syndrome, Pervasive Developmental Disorder.

What interventions are being tested in trial NCT04654260?

The interventions under investigation include: Behavioral Therapy for Irritability in Autism (BEHAVIORAL), Psychoeducation and Supportive Therapy (PST) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04654260?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04654260 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04654260's enrollment target sits among peer trials

65 114th of 224 higher than 111 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04654260, the US trial registry maintained by the National Library of Medicine. NCT04654260 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.